DK2222285T3 - Farmaceutiske sammensætninger - Google Patents

Farmaceutiske sammensætninger Download PDF

Info

Publication number
DK2222285T3
DK2222285T3 DK08848615.4T DK08848615T DK2222285T3 DK 2222285 T3 DK2222285 T3 DK 2222285T3 DK 08848615 T DK08848615 T DK 08848615T DK 2222285 T3 DK2222285 T3 DK 2222285T3
Authority
DK
Denmark
Prior art keywords
composition
amount
total weight
tablet
expressed
Prior art date
Application number
DK08848615.4T
Other languages
English (en)
Inventor
Erik Philipp
Ludwig Daniel Weibel
Original Assignee
Vifor (International) Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2222285(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor (International) Ag filed Critical Vifor (International) Ag
Application granted granted Critical
Publication of DK2222285T3 publication Critical patent/DK2222285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (25)

1. Farmaceutisk sammensætning omfattende jernoxid-hydroxid i høj koncentration på 10 til 80 % (vægt/vægt) udtrykt i forhold til den farmaceutiske sammensætnings samlede vægt, i en form der er egnet til oral indgivelse, hvor mængden af jernoxid-hydroxid pr. dosisform er > 300 mg.
2. Farmaceutisk sammensætning omfattende jernoxid-hydroxid i høj koncentration på 10 til 80 % (vægt/vægt) udtrykt i forhold til den farmaceutiske sammensætnings samlede vægt, i en form der er egnet til oral indgivelse som film-overtrukne dosisformer til intakt synkning eller som dosisformer der er i stand til at desintegrere i mundhulen, hvor mængden af jernoxid-hydroxid pr. dosisform er > 300 mg.
3. Sammensætning ifølge krav 1 eller 2, hvor sammensætningen indeholder mindst et kulhydrat og/eller huminsyre.
4. Sammensætning ifølge krav 3, hvor kulhydratet er valgt fra gruppen bestående af et mono-, di- eller polysaccharid, såsom agarose, dextran, dextrin, dextranderivater, cellulose og cellulosederivater, saccharose, maltose, og lactose, fortrinsvis saccharose, dextran, og stivelse.
5. Sammensætning ifølge et hvilket som helst af de foregående krav hvor jernoxid-hydroxidet indeholder beta jernoxid-hydroxid.
6. Sammensætning ifølge et hvilket som helst af de foregående krav hvor jernoxid-hydroxid er til stede i en mængde på 30 til 65 % (vægt/vægt), udtrykt i forhold til sammensætningens samlede vægt.
7. Sammensætning ifølge et hvilket som helst af de foregående krav hvor kulhydratet og/eller huminsyren er til stede i en samlet mængde på 1 til 50 % (vægt/vægt), fortrinsvis 5 til 30 % (vægt/vægt), udtrykt i forhold til sammensætningens samlede vægt.
8. Sammensætning ifølge et hvilket som helst af de foregående krav endvidere omfattende et eller flere aromastoffer, sødemidler, smagsfremmende midler, og/eller farvestoffer.
9. Sammensætning ifølge krav 8, hvor sødemidlet er naturligt eller ikke-naturligt sødemiddel valgt fra en sukker, en polyol, aspartam, sucralose, acesulfamin K, og/eller sakkarin og det smagsfremmende middel er valgt fra glycosider såsom neohesperidin-dihydrochalcon, glycyrrhizin, glutamat.
10. Sammensætning ifølge krav 8 eller 9, hvor sødemidlet er til stede i en mængde på 0,01 til 2,5 % (vægt/vægt), og det smagsfremmende middel i en mængde på 0,1 til 10 ppm, hver udtrykt i forhold til sammensætningens samlede vægt.
11. Sammensætning ifølge krav 8, hvor aromastoffet er til stede i en mængde på 0,01 til 10 % (vægt/vægt), fortrinsvis 0,1 til 5 % (vægt/vægt), mest fortrinsvis 0,1 til 1 % (vægt/vægt), udtrykt i forhold til sammensætningens samlede vægt.
12. Sammensætning ifølge et hvilket som helst af de foregående krav endvidere omfattende en eller flere excipienser, såsom super-desintegrationsmidler, glidemidler, antioxidanter.
13. Sammensætning ifølge krav 12, hvor super-desintegrationsmidlet er valgt fra gruppen bestående af tværbundne polyvinylpyrrolidoner, modificerede stivelser, og modificerede celluloser.
14. Sammensætning ifølge krav 12 eller 13, hvor super-desintegrationsmidlet er til stede i en mængde på 0,1 til 10% (vægt/vægt), fortrinsvis 0,5 til 8 % (vægt/vægt), mere fortrinsvis 2,5 til 6 % (vægt/vægt), udtrykt i forhold til sammensætningens samlede vægt.
15. Sammensætning ifølge krav 12, hvor glidemidlet er valgt fra gruppen bestående af magnesiumstearat, silikaderivater, såsom kolloid silika, pyrogen silika, hydreret natrium-aluminiumsilikat, kolloid siliciumdioxid, talkum og blandinger deraf, fortrinsvis magnesiumstearat, kolloid silika eller talkum.
16. Sammensætning ifølge krav 12 eller 15, hvor glidemidlet er til stede i en mængde på 0,01 til 10 % (vægt/vægt), fortrinsvis 0,1 til 5 % (vægt/vægt), udtrykt i forhold til sammensætningens samlede vægt.
17. Sammensætning ifølge et hvilket som helst af de foregående krav omfattende jernoxid-hydroxid i en mængde på 10 til 80 % (vægt/vægt), mindst et kulhydrat og/eller huminsyre i en samlet mængde på 1,0 til 50 % (vægt/vægt), eventuelt en eller flere excipienser i en samlet mængde på 1,0 til 50 % (vægt/vægt), et eller flere smagsfremmende midler i en samlet mængde på 0,1 til 10 ppm, og/eller et eller flere aromastoffer i en samlet mængde på 0,01 til 10 % (vægt/vægt), hver udtrykt i forhold til sammensætningens samlede vægt.
18. Sammensætning ifølge krav 17 omfattende et eller flere superdesintegrationsmidler i en samlet mængde på 0,1 til 10 vægtprocent (vægt/vægt).
19. Sammensætning ifølge et hvilket som helst af de foregående krav i form af en form til intakt synkning eller i en form der er i stand til hurtig at desintegrere såsom tyggetabletter eller piller, tørpulvere, granulater, kapsler eller små poser indeholdende disse granulater, oblater, eller pastiller.
20. Anvendelse af sammensætningerne ifølge et hvilket som helst af de foregående krav til fremstillingen af et medikament til behandlingen af hyperfosfatæmi.
21. Anvendelse af sammensætningerne ifølge et hvilket som helst af de foregående krav til fremstillingen af et medikament til behandlingen af patienter med kronisk nyreinsufficiens.
22. Fremgangsmåde til fremstilling af sammensætningen ifølge et hvilket som helst af de foregående krav i form af en tablet ved direkte komprimering eller tørgranulering.
23. Fremgangsmåde til fremstilling af sammensætningen ifølge et hvilket som helst af de foregående krav i form af en tablet, hvor en vandig suspension, omfattende mindst 90 % (vægt/vægt) af ingredienserne baseret på slutsammensætningens samlede vægt, fremstilles, som derefter underkastes sprøjtetørring for at opnå et flydbart pulver, som eventuelt blandes med de resterende ingredienser og efterfølgende komprimeres for at opnå en tablet.
24. Tablet, som er opnåelig med fremgangsmåden ifølge krav 23.
25. Tablet omfattende jernoxid-hydroxid i en mængde på 40 til 65 % (vægt/vægt), saccharose i en mængde på 5 til 30 % (vægt/vægt), og stivelse i en mængde på 5 til 30 % (vægt/vægt), udtrykt i forhold til tabletsammensætningens samlede vægt, eksklusiv vægten af en eventuelt tilstedeværende tablet-coating.
DK08848615.4T 2007-11-16 2008-11-13 Farmaceutiske sammensætninger DK2222285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07120837 2007-11-16
PCT/EP2008/065444 WO2009062993A1 (en) 2007-11-16 2008-11-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK2222285T3 true DK2222285T3 (da) 2017-02-06

Family

ID=39535152

Family Applications (4)

Application Number Title Priority Date Filing Date
DK21176696.9T DK3895699T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK16195982.0T DK3143992T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK08848615.4T DK2222285T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger
DK18191458.1T DK3492069T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK21176696.9T DK3895699T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK16195982.0T DK3143992T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18191458.1T DK3492069T3 (da) 2007-11-16 2008-11-13 Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid

Country Status (35)

Country Link
US (13) US9561251B2 (da)
EP (6) EP3143992B1 (da)
JP (7) JP5466164B2 (da)
KR (2) KR101590115B1 (da)
CN (7) CN112022796A (da)
AR (1) AR069312A1 (da)
AU (1) AU2008322963B2 (da)
BR (1) BRPI0820308B8 (da)
CA (1) CA2700444C (da)
CO (1) CO6280398A2 (da)
CY (3) CY1118496T1 (da)
DK (4) DK3895699T3 (da)
ES (5) ES2951457T3 (da)
FI (1) FI3895699T3 (da)
GT (1) GT201000144A (da)
HK (1) HK1207298A1 (da)
HR (4) HRP20220318T1 (da)
HU (2) HUE041429T2 (da)
IL (2) IL205726A (da)
LT (3) LT3492069T (da)
MA (1) MA31898B1 (da)
MX (1) MX2010005346A (da)
MY (2) MY156383A (da)
NZ (1) NZ585435A (da)
PH (1) PH12015500727B1 (da)
PL (4) PL3143992T3 (da)
PT (5) PT3895700T (da)
RU (2) RU2493831C3 (da)
SA (1) SA112340044B1 (da)
SG (1) SG188789A1 (da)
SI (4) SI2222285T1 (da)
TN (1) TN2010000152A1 (da)
TW (2) TWI468167B (da)
WO (1) WO2009062993A1 (da)
ZA (1) ZA201004256B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
MX2009008281A (es) 2007-02-06 2009-08-25 Medical Res Council Materiales de ion metalico de poli-oxo-hidroxi modificados con ligando, sus usos y procesos para su preparacion.
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
GB0814326D0 (en) * 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2014218455B2 (en) * 2009-07-21 2016-11-24 Keryx Biopharmaceuticals, Inc. Ferric Citrate Dosage Forms
CN109223724A (zh) * 2009-07-21 2019-01-18 凯克斯生物制药公司 柠檬酸铁剂型
US10624855B2 (en) 2013-11-27 2020-04-21 Vifor Fresenius Medical Care Renal Pharma Ltd. Pharmaceutical composition, comprising phosphate binder particles
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
EP3191219A1 (en) * 2014-09-10 2017-07-19 Lupin Limited A manufacturing process for an iron containing adsorbent
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CN107397759A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 基于铁的氢氧化物－降解的碳水化合物的磷结合剂、其制备方法及其应用
WO2020025552A1 (en) 2018-07-30 2020-02-06 Interquim, S.A. Process for preparing an adsorbent for phosphate in aqueous medium
JP7461295B2 (ja) * 2018-08-10 2024-04-03 キッセイ薬品工業株式会社 スクロオキシ水酸化鉄含有顆粒及び医薬組成物
RU2701738C1 (ru) * 2018-10-22 2019-10-01 Федеральное государственное бюджетное учреждение науки Институт химии нефти Сибирского отделения Российской академии наук (ИХН СО РАН) Способ получения композита на основе соединений железа
JP7320611B2 (ja) 2019-02-28 2023-08-03 レニバス・セラピューティクス・インコーポレイテッド 新規鉄組成物及びその製造方法と使用方法
US11090346B2 (en) * 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2021137780A1 (en) * 2019-12-30 2021-07-08 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Preparation of film tablet composition comprising heme iron for iron deficiency
AU2021208491A1 (en) * 2020-01-16 2022-08-18 Vifor Fresenius Medical Care Renal Pharma, Ltd. Particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide
EP3932535A1 (en) 2020-07-01 2022-01-05 Vifor Fresenius Medical Care Renal Pharma, Ltd. Manufacturing method for polynuclear iron compounds stabilized by carbohydrates and/or humic acid
CN113171353B (zh) * 2021-04-25 2022-10-21 海南普利制药股份有限公司 一种马来酸曲美布汀片
CN115155537B (zh) * 2022-07-28 2023-05-09 安徽农业大学 FeOOH功能化腈纶纤维及其制备方法和应用
CN116196330B (zh) * 2023-03-16 2024-09-20 广东赛康制药厂有限公司 一种治疗高磷酸血症药物的制备工艺

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820740A (en) 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
CH397628A (de) 1959-05-08 1965-08-31 Hausmann Ag Labor Verfahren zur Herstellung von therapeutisch verwendbaren Eisen-(III)-hydroxyd-Polymaltose-Komplexen
US3076798A (en) 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
AT279048B (de) 1967-07-04 1970-02-25 Pharmazeutische Fabrik Montavit Gmbh Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon
US3499837A (en) 1967-11-20 1970-03-10 Johns Manville Waste water treatment phosphate removal by iron oxide
GB1249558A (en) 1969-08-19 1971-10-13 American Cyanamid Co Process for the preparation of size-controlled colloidal iron sols and their stabilized solutions
US3928581A (en) 1972-09-13 1975-12-23 Astra Laekemedel Ab Certain polymer-iron complexes for treatment of iron deficiency
US4181718A (en) 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
CH650890A5 (de) 1981-06-15 1985-08-15 Edak Ag Tragbares schutzgehaeuse fuer elektrische und elektronische geraete.
US4474859A (en) 1982-02-05 1984-10-02 Jujo Paper Co., Ltd. Thermal dye-transfer type recording sheet
JPS5973576A (ja) * 1982-09-16 1984-04-25 グラクソ・グル−プ・リミテツド ピペリジニルシクロペンタノ−ルヘプテン酸塩
JPS5976535A (ja) 1982-10-22 1984-05-01 Kureha Chem Ind Co Ltd 収着剤およびその製造法
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4668400A (en) 1984-06-22 1987-05-26 Veech Richard L Hemodialysis processes and hemodialysis solutions
US5248492A (en) 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4869828A (en) 1988-02-26 1989-09-26 Nalco Chemical Company Stabilization of iron in aqueous systems
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
US5213692A (en) 1991-08-28 1993-05-25 Kemiron, Inc. Process for preparing preferred iron humates
TW271400B (da) * 1992-07-30 1996-03-01 Pfizer
DE69321531T2 (de) * 1992-08-04 1999-03-04 Toda Kogyo Corp., Hiroshima Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
DE4239442C2 (de) 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
PL197989B1 (pl) 1997-12-19 2008-05-30 Smithkline Beecham Corp Sposób wytwarzania szybko rozpraszających się tabletek do podawania doustnego, szybko rozpraszający się preparat farmaceutyczny w postaci tabletek i szybko rozpraszająca się, farmaceutycznie dopuszczalna, tabletka do podawania doustnego
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6156332A (en) 1999-05-27 2000-12-05 Ambi, Inc. Method and composition for masking mineral taste
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
AU7488001A (en) 2000-05-22 2001-12-03 Verion Inc Method for increasing the compressibility of poorly binding powder materials
US6358526B1 (en) 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
US6576665B2 (en) 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
WO2003032922A2 (en) 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
SI2172205T1 (sl) 2003-08-26 2014-10-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
US6903235B2 (en) 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
DE102004031181A1 (de) 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
CN100345546C (zh) * 2004-08-25 2007-10-31 浙江震元制药有限公司 氯诺昔康口腔速崩组合物及其制备方法
CN1302772C (zh) * 2005-05-24 2007-03-07 中国人民解放军第二军医大学 阿魏酸钠口腔崩解片及其制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
DK2319804T3 (da) 2006-12-14 2015-01-19 Novartis Ag Jern(III)-carbohydrat-baseret phosphatadsorbens
EP1932807A1 (en) * 2006-12-14 2008-06-18 Novartis AG Inorganic compounds
PT2319804E (pt) 2006-12-14 2014-11-24 Novartis Ag Adsorvente de fosfato à base de ferro (iii)-carboidrato
AU2013203333B2 (en) 2007-11-16 2015-04-02 Vifor (International) Ag Pharmaceutical compositions
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
GB0814326D0 (en) 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
US10624855B2 (en) 2013-11-27 2020-04-21 Vifor Fresenius Medical Care Renal Pharma Ltd. Pharmaceutical composition, comprising phosphate binder particles

Also Published As

Publication number Publication date
WO2009062993A1 (en) 2009-05-22
MX2010005346A (es) 2010-06-02
TWI468167B (zh) 2015-01-11
US10925896B2 (en) 2021-02-23
IL205726A0 (en) 2010-11-30
IL205726A (en) 2016-09-29
AR069312A1 (es) 2010-01-13
BRPI0820308A2 (pt) 2015-05-19
CN111789820A (zh) 2020-10-20
ES2703158T3 (es) 2019-03-07
HRP20170034T1 (hr) 2017-02-24
HUE041429T2 (hu) 2019-05-28
US20220105131A1 (en) 2022-04-07
CA2700444A1 (en) 2009-05-22
HRP20230588T3 (hr) 2023-09-01
US20190117686A1 (en) 2019-04-25
CY1125300T1 (el) 2024-02-16
US20220072035A1 (en) 2022-03-10
ES2703158T8 (es) 2020-10-28
ES2950337T3 (es) 2023-10-09
HRP20181837T1 (hr) 2019-02-08
EP3143992A1 (en) 2017-03-22
KR20100126266A (ko) 2010-12-01
IL247741B (en) 2020-11-30
BRPI0820308A8 (pt) 2019-10-29
EP3895700A3 (en) 2021-11-24
CN112022822A (zh) 2020-12-04
IL247741A0 (en) 2016-11-30
CN106619710A (zh) 2017-05-10
MY193729A (en) 2022-10-27
US20100247609A1 (en) 2010-09-30
RU2648760C2 (ru) 2018-03-28
RU2648760C3 (ru) 2019-12-16
RU2493831C3 (ru) 2017-06-08
PH12015500727A1 (en) 2015-12-14
PT3895699T (pt) 2023-07-20
PL3492069T3 (pl) 2022-05-30
EP3895699A2 (en) 2021-10-20
EP3895699B1 (en) 2023-04-26
AU2008322963A2 (en) 2010-04-22
US10925897B2 (en) 2021-02-23
US20200316112A1 (en) 2020-10-08
JP6294260B2 (ja) 2018-03-14
EP3492069A3 (en) 2019-08-28
CN104688702A (zh) 2015-06-10
SI2222285T1 (sl) 2017-05-31
US11013761B1 (en) 2021-05-25
JP6764959B2 (ja) 2020-10-07
HK1207298A1 (en) 2016-01-29
ES2951457T3 (es) 2023-10-23
JP7216055B2 (ja) 2023-01-31
PT3492069T (pt) 2022-03-08
RU2493831C2 (ru) 2013-09-27
AU2008322963B2 (en) 2014-04-24
US10682376B2 (en) 2020-06-16
US20200316111A1 (en) 2020-10-08
JP2017114873A (ja) 2017-06-29
GT201000144A (es) 2012-04-16
NZ585435A (en) 2012-07-27
CN101861146A (zh) 2010-10-13
DK3143992T3 (da) 2019-01-14
DK3492069T3 (da) 2022-03-14
PL2222285T3 (pl) 2017-06-30
TW200938210A (en) 2009-09-16
MY156383A (en) 2016-02-15
US20220105129A1 (en) 2022-04-07
LT2222285T (lt) 2017-02-10
EP2222285A1 (en) 2010-09-01
EP3492069B1 (en) 2022-02-16
JP2021001192A (ja) 2021-01-07
US10695367B2 (en) 2020-06-30
RU2013128356A (ru) 2014-12-27
US9561251B2 (en) 2017-02-07
EP3143992B1 (en) 2018-10-17
JP6538734B2 (ja) 2019-07-03
JP2015166359A (ja) 2015-09-24
EP3895700B1 (en) 2023-04-26
RU2010124424A (ru) 2011-12-27
EP3895699A3 (en) 2021-11-24
SA112340044B1 (ar) 2015-11-10
FI3895699T3 (fi) 2023-06-20
KR101590115B1 (ko) 2016-02-01
PH12015500727B1 (en) 2015-12-14
CY1118496T1 (el) 2017-07-12
SI3895699T1 (sl) 2023-08-31
TW201509423A (zh) 2015-03-16
EP3895700A2 (en) 2021-10-20
PT3895700T (pt) 2023-07-19
CY1121230T1 (el) 2020-05-29
DK3895699T3 (da) 2023-06-19
PL3143992T3 (pl) 2019-03-29
US10933090B2 (en) 2021-03-02
JP2019089805A (ja) 2019-06-13
HUE031293T2 (en) 2017-06-28
US20210137973A1 (en) 2021-05-13
EP2222285B1 (en) 2016-12-28
ZA201004256B (en) 2011-03-30
US20210128608A1 (en) 2021-05-06
HRP20220318T1 (hr) 2022-05-13
EP3895698A3 (en) 2021-11-24
US20190160096A1 (en) 2019-05-30
US10780113B2 (en) 2020-09-22
ES2908719T3 (es) 2022-05-03
CN112022821A (zh) 2020-12-04
KR101438071B1 (ko) 2014-09-04
JP5466164B2 (ja) 2014-04-09
EP3895698A2 (en) 2021-10-20
SG188789A1 (en) 2013-04-30
PL3895699T3 (pl) 2023-08-14
PT2222285T (pt) 2017-02-02
CA2700444C (en) 2017-01-17
JP2023011873A (ja) 2023-01-24
BRPI0820308B8 (pt) 2021-05-25
TN2010000152A1 (en) 2011-11-11
LT3143992T (lt) 2019-01-10
CN112022796A (zh) 2020-12-04
SI3143992T1 (sl) 2019-02-28
TWI592159B (zh) 2017-07-21
LT3492069T (lt) 2022-04-11
JP5961601B2 (ja) 2016-08-02
SI3492069T1 (sl) 2022-05-31
US20170100431A1 (en) 2017-04-13
US20220105130A1 (en) 2022-04-07
US11013762B1 (en) 2021-05-25
BRPI0820308B1 (pt) 2020-05-12
ES2612331T3 (es) 2017-05-16
EP3492069A2 (en) 2019-06-05
US20200345766A1 (en) 2020-11-05
JP2014062120A (ja) 2014-04-10
AU2008322963A1 (en) 2009-05-22
PT3143992T (pt) 2019-01-10
KR20130030306A (ko) 2013-03-26
MA31898B1 (fr) 2010-12-01
JP2011503148A (ja) 2011-01-27
CO6280398A2 (es) 2011-05-20

Similar Documents

Publication Publication Date Title
US11013761B1 (en) Pharmaceutical compositions
AU2013203333B2 (en) Pharmaceutical compositions